Syndax Pharmaceuticals (SNDX) Stock: Buy, Sell, or Hold?
SNDX - Syndax Pharmaceuticals, Inc.
$18.18
-0.64 (-3.40%)
▼
5d:
-12.09%
30d:
-8.18%
90d:
+1.51%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 02, 2026
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Sep 10, 2026 at $18.82 · last confirmed Sep 11, 2026
Strength: 7.7/10
Get Alerted When SNDX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: SNDX is down 12.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: SNDX is down 12.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: SNDX is currently trading at $18.18, which is considered oversold relative to its 30-day fair value range of $19.25 to $20.41. From a valuation perspective, the stock is trading at a discount (Forward PE: -22.3) compared to its historical average (126.3). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, SNDX is in a strong uptrend. The price is currently testing key support at $18.02. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: SNDX scores 31/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $37.55 (+106.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SNDX is in a strong uptrend. The price is currently testing key support at $18.02. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: SNDX scores 31/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $37.55 (+106.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$19.25 -
$20.41
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
Protect Your Profits
Holding SNDX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (31/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.4%)
- BULLISH: Trading 106.5% below Wall St target ($37.55)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 46/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$19.25 -
$20.41
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$18.02
Resistance Level
$21.00
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-22.28
Wall Street Target
$37.55
(+106.5%)
Revenue Growth (YoY)
91.8%
Profit Margin
-87.5%
PE vs Historical
-22.3 vs 126.3
CHEAP
Share & Embed Analysis
Last updated: September 13, 2026 3:26 AM ET
Data refreshes hourly during market hours. Next update: 4:26 AM
Data refreshes hourly during market hours. Next update: 4:26 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SNDX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$370 | 43 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$432 | 48 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$570 | 38 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$315 | 47 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
Advanced SNDX Option Strategies
Professional options setups generated by AI based on today's SNDX price and gamma walls.
